We have used genome-wide methylation microarrays to analyze differences in CpG methylation patterns in cells relevant to the pathogenesis of myeloma plasma cells, including B cells, normal plasma cells, MGUS, presentation myeloma, and plasma cell leukemia (PCL). We show that methylation patterns in these cell types are capable of distinguishing non-malignant from malignant cells and that the main reason for this difference is hypomethylation of the genome at the transition from MGUS to presentation myeloma. In addition, gene-specific hypermethylation was evident at the myeloma stage. Differential methylation was also evident at the transition from myeloma to PCL with re-methylation of the genome, particularly of genes involved in cell-cell signaling and cell adhesion, which may contribute to independence from the bone marrow microenvironment. There was a high degree of methylation variability within presentation myeloma samples and this was associated with the cytogenetic differences between samples. More specifically, we found that methylation subgroups were defined by translocations and hyperdiploidy, with t(4;14) myeloma having the largest impact on DNA methylation. Two groups of hyperdiploid samples were identified, based on unsupervised clustering, which had an impact on overall survival. Overall, DNA methylation changes significantly during disease progression and between cytogenetic subgroups.
Introduction
Upon encounter with antigen, naive B cells undergo somatic hypermutation and class switch recombination in the germinal center, finally differentiating into plasma cells residing in the bone marrow. 1 Multiple myeloma is a clonal malignancy of these plasma cells which develops as a consequence of a multistep transformation process. Insight into the molecular mechanisms underlying this transformation process can come from the study of the individual steps leading to myeloma which is known to evolve from a pre-malignant state, monoclonal gammopathy of undetermined significance (MGUS), and transforms into myeloma at a rate of 1% per year. 2, 3 Additional genetic events may transform the myeloma clone further to a more aggressive disease state known as plasma cell leukemia (PCL) where the clonal cells lose their dependency on the bone marrow microenvironment.
Genomic instability is a characteristic feature of myeloma cells where translocations involving the IGH locus and MMSET/FGFR3, CCND1, CCND3, MAF and MAFB occur, as well as numerous structural copy number alterations including del(1p), del(6q), del(8p), del(13q), del(16q), del (22) and gain of 1q. [4] [5] [6] However, the mechanisms involved in the progression from MGUS to myeloma are incompletely understood as, although present at decreased frequencies, the genetic markers characteristic of myeloma such as IGH rearrangements, hyperdiploidy, and gains and losses of chromosomal regions are also present in MGUS. 7, 8 While there has been substantial work on the genetics of myeloma little is known about the epigenetic changes leading to disease progression. Changes in DNA methylation status are one of the key epigenetic features known to regulate gene expression. Methylation changes occur primarily at CpG dinucleotides which are present at a higher frequency in promoter regions as well as within repeat sequences and transposable elements. 9 Hypomethylation in cancer cells mainly occurs within repeat sequences and transposable elements, whereas hypermethylation occurs in promoter regions, particularly of putative tumor suppressor genes. 10 Such hypermethylation of DNA is linked with transcriptionally inactive heterochromatin, and is associated with methylated histone H3K9 residues. 11-13 4 With the exception of one recent study 14 the epigenetic factors contributing to the pathogenesis of myeloma have been studied on a gene-by-gene basis and, using methylation specific PCR, several genes have been identified which are hypermethylated including VHL, XAF1, IRF8, TP53, CDKN2A, CDKN2B, DAPK, SOCS1, CDH1, PTGS2, CCND2 and DCC. [15] [16] [17] [18] [19] [20] [21] [22] Promoter hypermethylation of CDKN2A and TGFBR2 have been shown to correlate with poor prognosis in myeloma patients, although the prognostic value of CDKN2A hypermethylation remains debatable. 16, 23, 24 In this study we used the Infinium array (Illumina) to analyze CpG island promoter methylation using normal plasma cells, MGUS, myeloma and PCL samples in order to identify methylation changes which may contribute to the pathogenesis of myeloma, or that could act as prognostic factors.
Additionally, we utilized cytogenetic data available for the myeloma samples to identify methylation changes between known cytogenetic subgroups. These arrays have been used and validated by many groups and favorably correlate with whole-genome methylation sequencing technologies. [25] [26] [27] [28] 
Methods

Patient Samples and Clinical Data
The MRC Myeloma IX trial recruited 1970 newly diagnosed patients and comprised two arms; the first for older and less fit patients and the second for younger fitter patients. The details of the trial have been published elsewhere but in summary younger, fitter patients were put on the intensive arm and received autologous transplantation following induction with cyclophosphamide, thalidomide and dexamethasone (CTD) or cyclophosphamide, vincristine, doxorubicin and dexamethasone (CVAD). 29 The non-intensive arm consisted of older patients who were treated with either attenuated CTD (CTDa) or melphalan and prednisolone (MP). All patients were then randomized to thalidomide maintenance or no thalidomide maintenance. 
Expression Array Data
Expression array data are available for myeloma samples, have previously been published and are available under accession number GSE21349. 5
Data Analysis
Data were analyzed in GenomeStudio using the methylation module (Illumina).
Further analyses were performed using R and the LIMMA package. 33, 34 Missing elements in the data were imputed using row means. Differential methylation between samples were identified using an empirical Bayes moderated t-test and the resulting p-values were adjusted using the Benjamini and Hochberg method. 35 Pvalues below 0.05 were considered significant. Hierarchical clustering was performed using the Euclidean distance and Ward's method. 36 Cluster stability was ascertained with multiscale bootstrap analysis using the pvclust R package. 37 Approximately unbiased p-values were calculated using 100,000 resamplings of the original data. To further investigate the relationships shown using hierarchical clustering, principal component analysis was performed on the methylation data.
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Using a screeplot, the first three principal components were deemed to be significant and these data plotted against one another (see Supplementary Data).
Expression data were normalized using RMA (quantile normalized, median polish). 38, 39 Correlation between methylation and expression data was investigated using the Pearson correlation between the corresponding probes that mapped to the same gene symbol. Correlations were only considered if they were significantly different (p<0.05) from zero.
Results
Methylation Profiling of Different Disease Stages in Myeloma
Genome-wide methylation profiles were compared between normal B cells (n=6), normal plasma cells (n=3), MGUS samples (n=4), presentation myeloma (n=161), plasma cell leukemia (n=7) and human myeloma cell lines (HMCLs) (n=9). Using XY scatter plots significant variations in methylation profiles within the B cell subset of samples which were due to X-chromosome inactivation in females were noted. In order to remove these confounding data points we removed all probes present on the sex chromosomes leaving 26 486 probes on the array to interrogate.
Pair-wise comparisons on XY scatter plots were used to determine the variation in methylation within each cell type ( Figure 1 ). Correlation coefficients were determined and the range and median values are shown in Figure 1 and detailed in Table 1 . Median correlation coefficients >0.9 were seen in pre-malignant cell types such as B cells, normal plasma cells and MGUS plasma cells indicating a homogeneity of gene methylation between samples. However, in presentation myeloma, as well as in cell lines, the median correlation coefficients were <0.7
indicating a greater heterogeneity of methylation between samples of the same cell type. This heterogeneity may be the result of methylation variation between the different cytogenetic subgroups, and is investigated below.
The data for each probe were averaged over cell type and filtered to remove At the transition from myeloma to PCL the main changes are hypermethylation of genes (2151 probes, 1802 genes). Of these 2151 probes, 1412 are not within a CpG island meaning that there is methylation change both within and outside CpG islands. Interestingly, 1168 of these probes (1068 genes) were previously demethylated at the MGUS to myeloma transition consistent with re-methylation of previously de-methylated genes occurring at the transition to myeloma.
Gene Ontology (GO) analysis of the 82 probes (77 genes) hypermethylated at the transition to myeloma indicates that 3 main groups of genes affected are: regulation of developmental processes, cell cycle processes and regulation of transcription. 
Global Methylation Differences in Cytogenetic Subgroups
When the dataset is analyzed using an unsupervised clustering approach per Table 3 along with the corresponding methylation changes. C20orf103, which has similarity to LAMP domain proteins, was most differentially expressed with a 6.6-fold drop in expression in t(4;14) samples and a corresponding increase in methylation from 0.231 to 0.472. CD79A was also under-expressed in t(4;14) samples with an increase in methylation. This molecule has been found to have loss of protein expression in a subset of myeloma samples which also have low cyclin D1 expression. 42 These are likely to be t(4;14) samples, which are cyclin D2 positive, in which methylation of CD79A has resulted in loss of protein in the cells. Samples with cytogenetic abnormalities were also compared against those without the same abnormality. The abnormalities examined were del(1p32.3), gain 1q, del(13q), del(16q), del(17p), del(22q), hyperdiploidy, and any split IGH (Figure 3 , Table 2 ). In comparison to translocation subgroups these cytogenetic abnormalities are associated with far fewer methylation changes, indicating that these abnormalities are not significantly associated with methylation. The largest methylation changes were noted in the hyperdiploid comparison where 134 probes were hypomethylated and 194 were hypermethylated compared to non-hyperdiploid samples. Of interest in the non-hyperdiploid hypomethylated gene list was CCND1, in which 6 probes show a decrease in methylation. However, this difference in methylation did not correlate with a difference in expression of CCND1. When split by translocation group the decrease in methylation was not limited to the t (11;14) subgroup, which over-express CCND1, but was present in all the major translocation groups. In addition, hypermethylation of CCND1 within the hyperdiploid samples did not correlate with translocation/cyclin D (TC) classification status, indicating that methylation of CCND1 at these CpG sites is not linked to expression of the gene.
From unsupervised clustering of all samples we found 2 distinct groups of hyperdiploid samples, designated clades B and C (Figure 3) . There was no 13 disparity between the two groups with respect to the known cytogenetic markers, such as gain 1q or del(13q) which have been used by others to delineate hyperdiploid groups. 4 When the overall survival of samples within clades B and C are analyzed we found a significant difference (P=0.03, median OS 44.8 vs. >70 months; Figure 5 ) indicating methylation may have both clinical and biological effects within the HRD patients. A comparison between these two clades on the entire dataset gives 3174 differentially methylated probes, but the majority of these have a difference <0.2, leaving 209 probes with a statistically significant difference in methylation. Of these, 11 are more heavily methylated in clade B, which has the poorer OS, and include CDKN2A and CDKN2B (cell cycle inhibitors) and MAPT (microtubule associated protein).
Changes in methylation from myeloma to PCL
In order to more clearly delineate the changes in methylation pattern occurring from myeloma to PCL we compared samples with the same translocation in the 2 disease states. When comparing t(4;14) samples at myeloma (n=15) and PCL (n=2) stages we identified 618 probes (566 genes) as being significantly differentially methylated (Supplementary data). These probes were exclusively hypermethylated in t(4;14)
PCL compared to t(4;14) myeloma. When the same comparison was performed between t(11;14) myeloma (n=35) and t(11;14) PCL (n=3) we identified 566 probes (532 genes) which were differentially methylated, of which 560 were hypermethylated in PCL compared to myeloma. There were 71 genes commonly hypermethylated in both t(4;14) and t(11;14) PCL samples. Although the numbers of PCL samples are limited the consensus interpretation of these analyses is that there is an increase in methylation of CpG dinucleotides in the promoters of genes at the transition from myeloma to PCL. Pathway analysis of the genes in which methylation levels increase indicates that cytokine-cytokine receptor interaction and Jak/STAT signaling pathways are affected.
Discussion
In this study we used a genome-wide array approach to interrogate the methylation status of over 27 000 CpG sites. Using a selection of cell types relevant to the multistep pathogenesis of myeloma we have been able to determine the methylation changes which occur from normal plasma cells, through MGUS to presentation myeloma and plasma cell leukemia. We describe a clear distinction in methylation
pattern between non-malignant cells (B cells, normal plasma cells and MGUS cells)
compared with malignant plasma cells (presentation myeloma, PCL and HMCLs).
We also go on to show that the major differences in methylation profile are found at the transition of MGUS to myeloma and myeloma to PCL.
At the transition from MGUS to myeloma the key feature is an overwhelming loss of methylation. Such global hypomethylation is associated with genome instability in many cancer cell types including colorectal, gastric, breast and chronic lymphocytic leukemia. [45] [46] [47] [48] Genome hypomethylation is frequently linked to altered chromatin structure, changes in DNA methyltransferase activity, loss of imprinting and increased frequencies of copy number abnormalities. The resulting aberrant transcription and chromosomal instability within clones is likely to contribute to disease progression and is one of the critical differences distinguishing MGUS from myeloma. These results are not unique to the experimental approach used in this experiment and are consistent with a previous analysis of non-CpG element (LINE-1, Alu and SAT-α) methylation levels which show decreased methylation levels in myeloma compared with controls. 14 We also identified gene-specific hypermethylation at the transition of MGUS to myeloma involving 77 genes. Pathway analysis of the genes affected demonstrates involvement of developmental, cell cycle, and transcriptional regulatory pathways.
The genes involved include CALCA, ONECUT2, GATA4, and CDKN2B, but not CDKN2A or CDH1, all of which are known to be methylated in other cancer types. [49] [50] [51] The analysis of differentially methylated genes at the transition from MGUS to myeloma did not identify genes which have been shown to be methylated previously using methylation specific PCR. However, upon inspection of raw data we did find hypermethylation of some of these genes including CDKN2A, CDH1 and DCC in myeloma samples, but the spread of data points across the samples resulted in a pvalue >0.05 ( Supplementary Data) .
At the transition from myeloma to PCL, rather than finding further hypomethylation as may have been anticipated, we found further gene-specific hypermethylation with 1802 genes showing an increase in methylation status. In particular we show remethylation of genes involved in cell signaling and cell adhesion pathways which would be consistent with a mechanism whereby adhesion to the specialized bone marrow niche is impaired leading to bone marrow independent growth, allowing the tumor to enter the circulation and proliferate more freely. However, these data are based on a limited PCL sample cohort and require further investigation.
It is now widely accepted that there are two etiological subgroups of myeloma Cases with a t(4;14) over-express 2 potential oncogenes, MMSET and FGFR3, of which MMSET is of particular interest as it encodes a histone methyl transferase (HMT) which is known to methylate H3K36 and H4K20 residues and act as a transcriptional repressor. 52, 53 Pathway analysis of the genes hypermethylated in t(4;14) myeloma indicates a similar phenotype to that of PCL samples. The similarity in methylation profiles between t(4;14) myeloma and PCL suggest that methylation may significantly contribute to the more aggressive clinical phenotype seen in both disease subtypes.
There were a limited number of genes in the t(4;14) subgroup whose methylation status change correlated with gene expression changes. This limited correlation may reflect additional influences from other inactivating methods such as deletions, mutations (through nonsense mediated decay), and upstream activation or silencing of transcription factors. This is especially true of cell cycle inhibitors such as
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CDKN2A and CDKN2B which are also known to be deleted in myeloma samples. 5 In particular we have observed deletions of CDKN2C, located at 1p32, which do not correlate completely with loss of gene expression. This is, however, mostly seems to reflect the fact that expression of this gene is lost in >95% of myeloma samples, presumably through alternate mechanisms. 54 We believe that the correlation between methylation and gene expression will be equally complex.
An interesting observation in this study is our description of two specific subgroups of hyperdiploid myeloma based on their methylation profile. The TC classification of myeloma, while being a significant step forward, arguably does not deal adequately with the hyperdiploid group. In particular while the translocation subgroups have a distinct clinical outcome the hyperdiploid cases, amounting to 50% of the total, are apparently homogeneous in terms of their clinical outcome. Other groups have delineated groups of hyperdiploidy using mapping or expression array data. These analyses have been able to separate hyperdiploidy into groups based on the presence of 1q+,11+, NF-κB deregulation, proliferation or changes in the expression of cancer testis antigens. 4, 55 Here we show that it is possible to split hyperdiploid samples into 2, based on their methylation profiles, and that each of these groups has a significant difference in OS. These 2 groups are independent of cyclin D expression levels, cytogenetic abnormalities and of presenting clinical features.
Interestingly, we did not find a difference in the methylation status of NF-κB, proliferation or cancer testis antigens between the 2 groups, which may have led to the expression changes seen by other groups.
It is important to understand and develop models of how methylation changes may mediate the progressive transformation process from MGUS to myeloma. While it is clear from this analysis that genome-wide hypomethylation occurs at the transition from MGUS to myeloma, it is not so clear when gene-specific hypermethylation occurs. Hyperdiploidy and the main translocation groups (with the exception of t(4;14)) are present at similar frequencies in MGUS and presentation myeloma. As these cytogenetic abnormalities are the main defining feature of the methylation subgroups it may mean that these methylation groups also exist in MGUS cells, but we have not been able to analyze sufficient cases to demonstrate this adequately.
At the transition from MGUS to presentation myeloma secondary hits occur which result in genome hypomethylation. Whether these hits are mutations of genes controlling DNA methylation, such as DNA methyltransferases, or activation of transposable elements remains to be determined. 
